Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

This phase 1b trial studies the biologic effect of 9cUAB30 on early stage breast cancer.
9cUAB30 is a retinoid X receptor (RXR)-selective retinoid that acts in a tissue selective
manner with the goal of minimizing side effects, a necessary feature of agents under
development for cancer prevention.

Intervention

Retinoid 9cUAB30, Therapeutic Conventional Surgery

Condition

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8

Investigators

Helen Krontiras, Sonia L. Sugg, Jane Yuet Ching Hui, Lee G. Wilke

See list of participating sites